Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 149,293 shares of the medical research company’s stock after purchasing an additional 78 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Bio-Rad Laboratories were worth $49,044,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Venturi Wealth Management LLC lifted its holdings in Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 87 shares during the last quarter. Picton Mahoney Asset Management raised its position in Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 35 shares during the period. Asset Planning Inc acquired a new position in shares of Bio-Rad Laboratories in the 4th quarter valued at $33,000. UMB Bank n.a. grew its holdings in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth about $38,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 1.5 %

Shares of BIO stock opened at $243.33 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $241.87 and a fifty-two week high of $387.99. The company has a 50 day moving average price of $293.54 and a 200 day moving average price of $322.49. The stock has a market capitalization of $6.82 billion, a P/E ratio of -3.74 and a beta of 0.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analysts Set New Price Targets

BIO has been the topic of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.